A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults

[1]  Andrea De Maria,et al.  Immunology of Tuberculosis , 2014, Mediterranean journal of hematology and infectious diseases.

[2]  M. Demoitié,et al.  Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. , 2013, Vaccine.

[3]  Pierre Vandepapelière,et al.  The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study. , 2013, Tuberculosis.

[4]  S. Kaufmann,et al.  Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go? , 2012, PLoS pathogens.

[5]  M. Tameris,et al.  A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. , 2012, American journal of respiratory and critical care medicine.

[6]  S. Bertholet,et al.  The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine , 2012, The Journal of Immunology.

[7]  A. Izzo,et al.  BCG sub-strains induce variable protection against virulent pulmonary Mycobacterium tuberculosis infection, with the capacity to drive Th2 immunity. , 2011, Vaccine.

[8]  M. Tameris,et al.  Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. , 2011, The Journal of infectious diseases.

[9]  N. Garçon,et al.  Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems , 2011, Expert review of vaccines.

[10]  G. Schoolnik,et al.  A multistage tuberculosis vaccine that confers efficient protection before and after exposure , 2011, Nature Medicine.

[11]  G. Leroux-Roels,et al.  H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses , 2010, Journal of Clinical Immunology.

[12]  Y. Djuardi,et al.  A Longitudinal Study of BCG Vaccination in Early Childhood: The Development of Innate and Adaptive Immune Responses , 2010, PloS one.

[13]  G. Kaplan,et al.  Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. , 2010, American journal of respiratory and critical care medicine.

[14]  M. Demoitié,et al.  Evaluation of the Safety and Immunogenicity of Two Antigen Concentrations of the Mtb72F/AS02A Candidate Tuberculosis Vaccine in Purified Protein Derivative-Negative Adults , 2010, Clinical and Vaccine Immunology.

[15]  T. Ottenhoff,et al.  Multifunctional CD4+ T cells correlate with active Mycobacterium tuberculosis infection , 2010, European journal of immunology.

[16]  Ifedayo M. O. Adetifa,et al.  Expanded Polyfunctional T Cell Response to Mycobacterial Antigens in TB Disease and Contraction Post-Treatment , 2010, PloS one.

[17]  M. Tameris,et al.  The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. , 2010, American journal of respiratory and critical care medicine.

[18]  H. Dockrell,et al.  Complex cytokine profiles induced by BCG vaccination in UK infants , 2010, Vaccine.

[19]  S. Kaufmann,et al.  The quest for biomarkers in tuberculosis. , 2010, Drug discovery today.

[20]  M. Tameris,et al.  Modified vaccinia Ankara‐expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells , 2009, European journal of immunology.

[21]  J. Dietrich,et al.  Quality and Vaccine Efficacy of CD4+ T Cell Responses Directed to Dominant and Subdominant Epitopes in ESAT-6 from Mycobacterium tuberculosis1 , 2009, The Journal of Immunology.

[22]  G. Bjune,et al.  The protective role of antibody responses during Mycobacterium tuberculosis infection , 2009, Clinical and experimental immunology.

[23]  Joe D. Cohen,et al.  The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans , 2009, Human vaccines.

[24]  Sugata Roy,et al.  Distinct Differences in the Expansion and Phenotype of TB10.4 Specific CD8 and CD4 T Cells after Infection with Mycobacterium tuberculosis , 2009, PloS one.

[25]  J. Dietrich,et al.  Protection and Polyfunctional T Cells Induced by Ag85B-TB10.4/IC31® against Mycobacterium tuberculosis Is Highly Dependent on the Antigen Dose , 2009, PloS one.

[26]  P. Andersen,et al.  Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells1 , 2009, The Journal of Immunology.

[27]  R. Davies,et al.  Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. , 2009, American journal of respiratory and critical care medicine.

[28]  V. Maino,et al.  Standardization and optimization of multiparameter intracellular cytokine staining , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[29]  M. Newport,et al.  Natural Variation in Immune Responses to Neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian Infants , 2008, PloS one.

[30]  T. Lang,et al.  Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. , 2008, The Journal of infectious diseases.

[31]  U. Wahn,et al.  Mycobacterium tuberculosis-specific CD4+, IFNgamma+, and TNFalpha+ multifunctional memory T cells coexpress GM-CSF. , 2008, Cytokine.

[32]  H. Dockrell,et al.  Persistence of the immune response induced by BCG vaccination , 2008, BMC infectious diseases.

[33]  R. Koup,et al.  Immunisation with BCG and recombinant MVA85A induces long‐lasting, polyfunctional Mycobacterium tuberculosis‐specific CD4+ memory T lymphocyte populations , 2007, European journal of immunology.

[34]  P. Chomez,et al.  GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.

[35]  B. Anuradha,et al.  Age-related waning of in vitro Interferon-γ levels against r32kDaBCG in BCG vaccinated children , 2007, Journal of immune based therapies and vaccines.

[36]  G. Rook.  Th2 cytokines in susceptibility to tuberculosis. , 2007, Current molecular medicine.

[37]  Alimuddin Zumla,et al.  Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not. , 2006, Tuberculosis.

[38]  C. Dye,et al.  Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness , 2006, The Lancet.

[39]  S. Stenger.  Immunological control of tuberculosis: role of tumour necrosis factor and more , 2005, Annals of the rheumatic diseases.

[40]  Andreas Thiel,et al.  Direct access to CD4+ T cells specific for defined antigens according to CD154 expression , 2005, Nature Medicine.

[41]  Mario Roederer,et al.  A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles , 2005, Nature Medicine.

[42]  Alimuddin Zumla,et al.  Immune responses to tuberculosis in developing countries: implications for new vaccines , 2005, Nature Reviews Immunology.

[43]  Alimuddin Zumla,et al.  Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting? , 2005, Vaccine.

[44]  S. Reed,et al.  Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, Mtb72F, Delivered as Naked DNA or Recombinant Protein1 , 2004, The Journal of Immunology.

[45]  S. Hansen,et al.  Duration of antiviral immunity after smallpox vaccination , 2003, Nature Medicine.

[46]  E. Chan,et al.  Current medical treatment for tuberculosis , 2002, BMJ : British Medical Journal.

[47]  C. Locht,et al.  The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination , 2001, Nature.

[48]  M. Newport,et al.  Neonatal bacillus Calmette‐Guérin vaccination induces adult‐like IFN‐γ production by CD4+ T lymphocytes , 2001, European journal of immunology.

[49]  S. Kunkel,et al.  Interleukin 4 and 13 participation in mycobacterial (type-1) and schistosomal (type-2) antigen-elicited pulmonary granuloma formation: multiparameter analysis of cellular recruitment, chemokine expression and cytokine networks. , 2000, Cytokine.

[50]  J. Sterne,et al.  Does the efficacy of BCG decline with time since vaccination? , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[51]  P. E. M. Fine,et al.  Variation in protection by BCG: implications of and for heterologous immunity , 1995, The Lancet.

[52]  R. Coffman,et al.  Modulation of murine macrophage function by IL-13. , 1993, Journal of immunology.

[53]  H. Maecker.  Multiparameter flow cytometry monitoring of T cell responses. , 2009, Methods in molecular biology.

[54]  J. Flynn.  Immunology of tuberculosis and implications in vaccine development. , 2004, Tuberculosis.

[55]  马建新,et al.  呼吸机相关性肺炎的非侵入性与侵入性检查 [英]／Ruiz M…／／Am J Respir Crit Care Med , 2002 .

[56]  S. Reed,et al.  Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. , 1999, Infection and immunity.

[57]  R. Coler,et al.  Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. , 1999, Infection and immunity.

[58]  Global Tuberculosis Programme.  Global tuberculosis control : WHO report , 1997 .